Rakesh K Goyal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8811679/publications.pdf

Version: 2024-02-01

69 papers

1,694 citations

304743 22 h-index 289244 40 g-index

71 all docs

71 docs citations

71 times ranked 3021 citing authors

#	Article	IF	CITATIONS
1	The genomic landscape of juvenile myelomonocytic leukemia. Nature Genetics, 2015, 47, 1326-1333.	21.4	233
2	TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood, 2009, 113, 309-316.	1.4	129
3	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood, 2014, 123, 2017-2025.	1.4	109
4	Ajuba, a Novel LIM Protein, Interacts with Grb2, Augments Mitogen-Activated Protein Kinase Activity in Fibroblasts, and Promotes Meiotic Maturation of <i>Xenopus</i> Oocytes in a Grb2- and Ras-Dependent Manner. Molecular and Cellular Biology, 1999, 19, 4379-4389.	2.3	94
5	Lung Function, Pulmonary Complications, and Mortality after Allogeneic Blood and Marrow Transplantation in Children. Biology of Blood and Marrow Transplantation, 2009, 15, 817-826.	2.0	85
6	Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young Children: The Cord Blood Transplantation Study (COBLT) Experience. Biology of Blood and Marrow Transplantation, 2005, 11, 637-646.	2.0	76
7	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). Biology of Blood and Marrow Transplantation, 2015, 21, 67-73.	2.0	62
8	Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD. Journal of Allergy and Clinical Immunology, 2017, 139, 1032-1035.e6.	2.9	62
9	Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Human Genetics, 2006, 119, 276-283.	3.8	58
10	The Ajuba LIM Domain Protein Is a Corepressor for SNAG Domain–Mediated Repression and Participates in Nucleocytoplasmic Shuttling. Cancer Research, 2007, 67, 9097-9106.	0.9	58
11	Focal nodular hyperplasia of the liver: a sequela of tumor therapy. Pediatric Radiology, 2005, 35, 1234-1239.	2.0	54
12	Unrelated Donor Bone Marrow Transplantation for Children With Acute Myeloid Leukemia Beyond First Remission or Refractory to Chemotherapy. Journal of Clinical Oncology, 2008, 26, 4326-4332.	1.6	51
13	The Amino Terminus of the Glial Glutamate Transporter GLT-1 Interacts with the LIM Protein Ajuba. Molecular and Cellular Neurosciences, 2002, 19, 152-164.	2.2	49
14	Related and unrelated donor transplantation for \hat{l}^2 -thalassemia major: results of an international survey. Blood Advances, 2019, 3, 2562-2570.	5.2	48
15	Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. Frontiers in Immunology, 2017, 8, 798.	4.8	41
16	Anemia in Children With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 563-582.	1.8	36
17	Voriconazole-associated phototoxic dermatoses and skin cancer. Expert Review of Anti-Infective Therapy, 2015, 13, 1537-1546.	4.4	30
18	Outcomes of Hematopoietic Cell Transplantation in Patients with Germline SAMD9/SAMD9L Mutations. Biology of Blood and Marrow Transplantation, 2019, 25, 2186-2196.	2.0	30

#	Article	IF	CITATIONS
19	Pulmonary complications of haematopoietic cell transplantation in children. Paediatric Respiratory Reviews, 2007, 8, 46-61.	1.8	28
20	Abnormalities of T-cell receptor repertoire in CD4+ regulatory and conventional T cells in patients with RAG mutations: Implications for autoimmunity. Journal of Allergy and Clinical Immunology, 2017, 140, 1739-1743.e7.	2.9	28
21	Neonatal Lupus and IUGR Following Alpha-Interferon Therapy during Pregnancy. Journal of Perinatology, 2005, 25, 552-554.	2.0	27
22	A Phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft <i>versus</i> host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). British Journal of Haematology, 2009, 147, 691-699.	2.5	27
23	Hodgkin Disease After Renal Transplantation in Childhood. Journal of Pediatric Hematology/Oncology, 1996, 18, 392-395.	0.6	21
24	Clofazimine enteropathy in a pediatric bone marrow transplant recipient. Journal of Pediatrics, 2001, 138, 574-576.	1.8	21
25	Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow Transplantation in Children: A Pediatric Blood and Marrow Transplant Consortium Study. Biology of Blood and Marrow Transplantation, 2010. 16. 927-936.e1.	2.0	21
26	Phototoxic dermatoses in pediatric BMT patients receiving voriconazole. Pediatric Blood and Cancer, 2014, 61, 1325-1328.	1.5	20
27	The management of menstrual suppression and uterine bleeding: A survey of current practices in the pediatric blood and marrow transplant consortium. Pediatric Blood and Cancer, 2012, 59, 553-557.	1.5	19
28	A Pilot Study of Heel Ultrasound to Screen for Low Bone Mass in Children With Leukemia. Journal of Pediatric Hematology/Oncology, 2006, 28, 427-432.	0.6	15
29	Development and Validation of a High-Performance Liquid Chromatographic Assay for the Determination of Fluconazole in Human Whole Blood Using Solid Phase Extraction. Therapeutic Drug Monitoring, 2008, 30, 314-319.	2.0	13
30	Advancement of Pediatric Blood and Marrow Transplantation Research in North America: Priorities of the Pediatric Blood and Marrow Transplant Consortium. Biology of Blood and Marrow Transplantation, 2010, 16, 1212-1221.	2.0	11
31	Sirolimusâ€induced interstitial lung disease following pediatric stem cell transplantation. Pediatric Transplantation, 2015, 19, E75-7.	1.0	11
32	High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Advances, 2022, 6, 452-459.	5.2	11
33	Abnormalities of Cytokine Receptor Signalling Contributing to Diseases of Red Blood Cell Production. Annals of Medicine, 1999, 31, 208-216.	3.8	9
34	Sirolimus Pharmacokinetics in Early Postmyeloablative Pediatric Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 569-575.	2.0	9
35	Grading acute graftâ€versusâ€host disease: Time to reconsider. Pediatric Transplantation, 2015, 19, 252-254.	1.0	9
36	Outcome of children with rhinovirus detection prior to allogeneic hematopoietic cell transplant. Pediatric Transplantation, 2018, 22, e13301.	1.0	9

#	Article	IF	CITATIONS
37	A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. Biology of Blood and Marrow Transplantation, 2016, 22, 682-689.	2.0	8
38	Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies. Pediatric Blood and Cancer, 2018, 65, e26776.	1.5	7
39	Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection. , 2021, 9, e001225.		6
40	Successful engraftment following unrelated donor transplant in an alloimmunized patient with Kostmann syndrome. Pediatric Blood and Cancer, 2005, 44, 508-510.	1.5	5
41	Treatment of pediatric plasma cell myeloma type postâ€transplant lymphoproliferative disorder with modern riskâ€directed therapy. Pediatric Blood and Cancer, 2018, 65, e27283.	1.5	5
42	Safety and Efficacy of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil \hat{A}^{\otimes}) + G-CSF In Pediatric Patients with Malignant Disorders. Blood, 2010, 116, 2245-2245.	1.4	5
43	The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse. Blood, 2012, 120, 470-470.	1.4	4
44	Relapsed non-Hodgkin's lymphoma diagnosed by flexible bronchoscopy. Pediatric Pulmonology, 2002, 34, 488-490.	2.0	3
45	Models for anti-tumor activity of bisphosphonates using refined topochemical descriptors. Die Naturwissenschaften, 2011, 98, 871-887.	1.6	3
46	Metaâ€nnalyzing the link between <i>MTHFR</i> C677T genotype and susceptibility to childhood ALL. Pediatric Blood and Cancer, 2012, 58, 483-484.	1.5	3
47	Grading Acute GVHD: Getting It Right Every Time!. Biology of Blood and Marrow Transplantation, 2015, 21, S118.	2.0	3
48	Using Ultrasound Elastography to Predict Which Pediatric HSCT Patients Will Develop Severe Sinusoidal Obstruction Syndrome. Biology of Blood and Marrow Transplantation, 2019, 25, S43-S44.	2.0	2
49	A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders. Transfusion, 2021, 61, 894-902.	1.6	2
50	Tacrolimus Versus Cyclosporine for Graft-Versus-Host Disease Prophylaxis in Pediatric Patients Undergoing Matched Unrelated Donor Hematopoietic Stem Cell Transplants. A Pediatric Blood and Marrow Transplant Consortium Study Blood, 2006, 108, 2883-2883.	1.4	2
51	Refractory Graft Versus Host Disease in Children: Is Photopheresis the Answer?. Journal of Pediatric Hematology/Oncology, 2007, 29, 731-732.	0.6	1
52	MTHFR 677 C>T genotype and adverse outcomes in treatment of childhood ALL: Is the jury in?. Pediatric Blood and Cancer, 2009, 52, 316-317.	1.5	1
53	Excellent Outcomes Using Reduced-Intensity Conditioning for Patients with Inborn Errors of Immunity, Hematopoiesis, and Metabolism. Biology of Blood and Marrow Transplantation, 2016, 22, \$100-\$101.	2.0	1
54	Forced deflation pulmonary function test: a novel method to evaluate lung function in infants and young children. Pediatric Blood and Cancer, 2017, 64, e26356.	1.5	1

#	Article	IF	CITATIONS
55	Successful Engraftment Using Varied Stem Cell Sources, Low Toxicity, and Long-Term Survival Using a Bu/Flu/ATG Reduced Intensity Allogeneic Transplantation in High Risk Pediatric Patients Ineligible for Myelablative Therapy: Results of the Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study ONC0313 Blood, 2007, 110, 623-623.	1.4	1
56	Plerixafor Is Highly Effective for the Mobilization of Autologous PBSC for Transplant in Children Failing to Mobilize by Conventional Means: International Experience with 40 Children From 19 Centers. Blood, 2011, 118, 1931-1931.	1.4	1
57	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. Blood, 2011, 118, 837-837.	1.4	1
58	Cord blood lymphocytes show higher ATP production compared to peripheral blood lymphocytes from children and adults. Journal of Neonatal-Perinatal Medicine, 2009, 2, 261-265.	0.8	0
59	Hematopoietic stem cell transplant: Does congenital heart disease matter?. Pediatric Transplantation, 2011, 15, 7-8.	1.0	0
60	Reduced Intensity Conditioning Regimen Combined with Single Unit Cord Blood Transplantation Is Effective and Safe for Children with Inherited Metabolic Disorders and Combined Immunodeficiency Diseases. Biology of Blood and Marrow Transplantation, 2014, 20, S88-S89.	2.0	0
61	Adrenocortical Function in Children With Brain Tumors and Pediatric Hematopoietic Cell Transplantation Recipients. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, .	0.6	0
62	Identification and Effects of Novel Promoter Region Haplotypes in the Human Equilibrative Nucleoside Transporter, hENT1 Blood, 2004, 104, 2083-2083.	1.4	0
63	Identification and Effects of Novel Promoter Region Haplotypes in the Human Cytidine Deaminase Gene Blood, 2004, 104, 2080-2080.	1.4	0
64	Calcitonin A Genotype Is Associated with Risk of Acute Graft-Versus-Host Disease Following Allogeneic Bone Marrow Transplantation for Children with Acute Myeloid Leukemia in First Remission Blood, 2005, 106, 1813-1813.	1.4	0
65	Low Rates of Toxicity, GVHD, and Relapse Using Sirolimus (SRL)-Based GVHD Prophylaxis in Pediatric Related and Unrelated Transplant Recipients with High-Risk ALL Blood, 2006, 108, 2876-2876.	1.4	O
66	Chronic Graft-Versus-Host Disease after Tacrolimus Versus Cyclosporine for Graft-Versus-Host Disease Prophylaxis in Pediatric Patients Undergoing Matched Unrelated Donor Hematopoietic Stem Cell Transplantation. A Pediatric Blood and Marrow Transplant Consortium Study Blood, 2007, 110, 4984-4984.	1.4	0
67	A Pilot Study Of Continuous Infusion Mycophenolate Mofetil For Graft Versus Host Disease Prophylaxis. Blood, 2013, 122, 4571-4571.	1.4	0
68	Excellent Outcomes in Children and Young Adults Using Reduced-Intensity Conditioning for Patients with Inborn Errors of Immunity, Hematopoiesis, and Metabolism with Single-Unit Cord Blood or Bone Marrow. Blood, 2015, 126, 4329-4329.	1.4	0
69	Cathelicidin Antimicrobial Peptide Expression Is Inversely Associated with Absolute Neutrophil Counts in Pediatric HCT Recipients. Blood, 2019, 134, 3294-3294.	1.4	O